表 4.
不同生物标志物表达组间患者疗效汇总
Efficacy summary by biomarker status
| Items | PD-L1+ (n=55) | PD-L1- (n=62) | MSI-H (n=9) | ||||
| Atezolizumab (n=42) | Atezolizumab + gemcitabine + cisplatin (n=13) | Atezolizumab (n=56) | Atezolizumab + gemcitabine + cisplatin (n=6) | Atezolizumab (n=9) | |||
| Abbreviations and explain as in Figure 1, Table 1 and 3. a, DCR is calculated by taking the sum of CR, PR, and SD. | |||||||
| ORR (95%CI)/% | 11.9 (3.98-25.63) | 46.2 (19.22-74.87) | 8.9 (2.96-19.62) | 33.3 (4.33-77.72) | 11.1 (0.28-48.25) | ||
| CR, n(%) | 0 | 0 | 0 | 0 | 0 | ||
| PR, n(%) | 5 (11.9) | 6 (46.2) | 5 (8.9) | 2 (33.3) | 1 (11.1) | ||
| SD, n(%) | 16 (38.1) | 5 (38.5) | 25 (44.6) | 4 (66.7) | 4 (44.4) | ||
| DCRa, n(%) | 21 (50.0) | 11 (84.6) | 30 (53.6) | 6 (100.0) | 5 (55.6) | ||
| PD, n(%) | 17 (40.5) | 1 (7.7) | 21 (37.5) | 0 | 4 (44.4) | ||
| NE, n(%) | 0 | 0 | 0 | 0 | 0 | ||
| Missing, n(%) | 4 (9.5) | 1 (7.7) | 5 (8.9) | 0 | 0 | ||
| Median DOR (95%CI)/months | 20.8 (6.9-20.8) | NE (5.6-NE) | 17.1 (8.0-NE) | NE (NE) | NE | ||
| Median PFS (95%CI)/months | 2.8 (1.4-4.4) | 6.9 (5.5-NE) | 2.7 (1.4-3.8) | 5.8 (3.3-NE) | 4.2 (1.4-15.0) | ||
| Median OS (95%CI)/months | 14.9 (6.1-29.9) | NE (9.6-NE) | 9.7 (6.6-13.2) | NE (3.8-NE) | 15.0 (9.7-NE) | ||
| 6-month OS rate (95%CI)/% | 67 (52-82) | 100 (100-100) | 64 (52-77) | 67 (29-100) | 78 (51-100) | ||
| 1-year OS rate (95%CI)/% | 50 (34-67) | 75 (33-100) | 39 (26-52) | NE (NE) | 65 (32-97) | ||
| Duration of follow-up/months, M (Range) | NA | NA | NA | NA | NA | ||